((自动化翻译由路透提供，请见免责声明 )) (更新)
11月29日 - ** 应用治疗公司 股价下跌72.1% ，至2.39 美元，创下单日跌幅纪录
** 美国食品和药物管理局（FDA）周三拒绝 (link)，批准APLT公司治疗半乳糖血症（一种罕见的遗传代谢疾病）的药物。
** APLT公司称，FDA在信中提到了这种名为 "govorestat "的药物 "临床申请中的不足之处"。
** 经纪公司威廉-布莱尔（William Blair）表示，这封信 "出乎意料，令人失望"，但认为它不会增加 govorestat 用于治疗另一种罕见遗传代谢病 SORD 缺乏症的审批风险。
** 包括本交易日损失在内，该股今年累计下跌28.4
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.